Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry by Mena Vázquez, Natalia et al.
Original article
Hydroxychloroquine is associated with a lower
risk of polyautoimmunity: data from the
RELESSER Registry
Natalia Mena-Vázquez1,2, Antonio Fernández-Nebro1,2,3,
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Objectives. This article estimates the frequency of polyautoimmunity and associated factors in a large retrospect-
ive cohort of patients with SLE.
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Methods. RELESSER (Spanish Society of Rheumatology Lupus Registry) is a nationwide multicentre, hospital-
based registry of SLE patients. This is a cross-sectional study. The main variable was polyautoimmunity, which
was defined as the co-occurrence of SLE and another autoimmune disease, such as autoimmune thyroiditis, RA,
scleroderma, inflammatory myopathy and MCTD. We also recorded the presence of multiple autoimmune syn-
drome, secondary SS, secondary APS and a family history of autoimmune disease. Multiple logistic regression ana-
lysis was performed to investigate possible risk factors for polyautoimmunity.
Results. Of the 3679 patients who fulfilled the criteria for SLE, 502 (13.6%) had polyautoimmunity. The most fre-
quent types were autoimmune thyroiditis (7.9%), other systemic autoimmune diseases (6.2%), secondary SS
(14.1%) and secondary APS (13.7%). Multiple autoimmune syndrome accounted for 10.2% of all cases of polyau-
toimmunity. A family history was recorded in 11.8%. According to the multivariate analysis, the factors associated
with polyautoimmunity were female sex [odds ratio (95% CI), 1.72 (1.07, 2.72)], RP [1.63 (1.29, 2.05)], interstitial
lung disease [3.35 (1.84, 6.01)], Jaccoud arthropathy [1.92 (1.40, 2.63)], anti-Ro/SSA and/or anti-La/SSB autoanti-
bodies [2.03 (1.55, 2.67)], anti-RNP antibodies [1.48 (1.16, 1.90)], MTX [1.67 (1.26, 2.18)] and antimalarial drugs
[0.50 (0.38, 0.67)].
Conclusion. Patients with SLE frequently present polyautoimmunity. We observed clinical and analytical charac-
teristics associated with polyautoimmunity. Our finding that antimalarial drugs protected against polyautoimmunity
should be verified in future studies.
Key words: polyautoimmunity, systemic lupus erythematosus, multiple autoimmune syndrome
Introduction
SLE is a systemic autoimmune rheumatic disease
(SARD) that can affect any tissue and lead to a wide
range of clinical manifestations that are shared by other
inflammatory diseases [1]. Polyautoimmunity is the co-
occurrence of more than one well-defined autoimmune
disease in the same patient. The co-occurrence of three
or more autoimmune diseases is known as multiple
autoimmune syndrome (MAS), which is an extreme
phenotype of polyautoimmunity. Patients with SLE often
present with autoimmune thyroiditis, SS, RA, auto-
immune hepatitis or APS [2]. Overlap syndrome is
defined as the co-occurrence of manifestations of sev-
eral recognized and diagnostically confirmed auto-
immune diseases in the same patient [3], although this
area remains open to debate [4]. One example would be
MCTD, which shares clinical characteristics with SLE,
SSc, PM/DM and RA. Patients with this condition also
have high ANA titres (anti-RNP), and their main symp-
toms are polyarthritis, hand oedema, RP, sclerodactyly,
myositis and oesophageal hypomobility [5]. The subject
of whether this disease is a separate entity or a transi-
tional syndrome remains controversial [6]. The main
objections are as follows: (i) patients can progress to an-
other well-defined SARD; (ii) anti-RNP antibodies are not
exclusive to this condition, and the most typical clinical
manifestations of MCTD co-occur with other antibodies;
and (iii) there are no widely accepted classification crite-
ria [7, 8].
Both polyautoimmunity and overlap syndromes, together
with familial aggregation of autoimmune diseases, repre-
sent phenotypic expressions of an identical or similar
genotype and of ‘immune tautology’. Study of some of the
characteristics of patients with SLE, polyautoimmunity and
overlap syndromes (epidemiology, familial coaggregation,
shared pathophysiology, genetic factors and similar treat-
ments) has revealed no clear distinction between pheno-
typic subgroups [4, 9, 10]; therefore, it would be interesting
to know how polyautoimmunity affects patients with SLE.
Increased knowledge would provide us with information on
the frequency and clinical characteristics of the condition
and pave the way for new lines of research into the clinical
significance of and mechanisms involved in autoimmunity.
The aims of the present study were as follows: (i) to
investigate the prevalence of polyautoimmunity and
MAS in a large cohort of patients with SLE in Spain; (ii)
to describe the characteristics of subphenotypes; and
(iii) to identify factors associated with polyautoimmunity
in patients with SLE.
Methods
RELESSER Registry
We performed a retrospective evaluation of all adult
patients in the RELESSER Registry (Spanish Society of
Rheumatology key messages
. Antimalarial drugs could delay the development of polyautoimmunity in SLE patients.
Anti-Ro/SSA, anti-La/SSB and anti-RNP antibodies were independently associated with polyautoimmunity in
SLE patients.
. Polyautoimmunity in SLE patients was associated with Jaccoud arthropathy, RP and interstitial lung disease.
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Rheumatology Lupus Registry) to determine the
prevalence of polyautoimmunity and MAS in patients
with SLE.
The RELESSER Registry is a nationwide multicentre,
hospital-based registry involving a cross-sectional stage
designed by the Systemic Autoimmune Diseases
Working Group of the Spanish Society of Rheumatology
[11]. The methodologic and general characteristics of
the RELESSER Registry have been published elsewhere
[12, 13]. The registry includes cumulative clinical data
for patients with SLE in clinical settings. The Research
Unit of the Spanish Society of Rheumatology was the
coordinating centre and was responsible for providing
expert methodological support at all stages of the pro-
ject, monitoring the study, and identifying and resolving
inconsistencies.
Written commitment was obtained from all investiga-
tors prior to participation. The study was approved by
the Ethics Committee at Dr Negrı́n University Hospital,
Gran Canaria, Spain, and then by the institutional re-
search review boards at all participating centres.
Informed consent was obtained from the patients. The
study was conducted in accordance with the
Declaration of Helsinki.
Study population
We selected adult patients with SLE defined according
to the 1997 criteria of the ACR [14]. All patients had
been attended and followed at any one of 45 Spanish
rheumatology teaching centres with experience in the
treatment of SLE. Patients were widely and homoge-




Patients were considered to have polyautoimmunity
when they simultaneously fulfilled the classification crite-
ria for SLE classified according to the ACR 1997 criteria
[14] and another autoimmune disease, such as auto-
immune thyroiditis (abnormal thyroid function with
antithyroid antibodies), MCTD according to the criteria
of Alarcón-Segovia and Cardiel [15], other autoimmune
diseases such as RA according to the criteria of the
ACR [16], SSc [17] and inflammatory myopathy [18].
MAS was defined as the co-occurrence of SLE and at
least two other autoimmune diseases (see above).
Other outcomes
We also recorded whether patients had secondary SS
according to the criteria of the 2002 American-European
Consensus Group [19], APS according to the Sydney
criteria [20] or a family history (first- or second-degree)
of SARD. However, these forms were not counted as
polyautoimmunity but as secondary syndromes.
We also recorded demographic, clinical, analytical
and treatment data. Demographic and clinical variables
included age (in years), sex, comorbidities included in
the Charlson index [21], date of onset of the disease
(date the patient first fulfilled four or more ACR or SLE
criteria), duration of the disease (calculated from diagno-
sis to the most recent visit or death, if applicable), and
all of the parameters covered in the ACR and SLE clas-
sification criteria. Analytical data were assessed in the
local laboratory. We recorded all present or past drugs
and the reasons for interrupting them, nonpharmacologi-
cal treatments and mortality. At the last visit, we retro-
spectively recorded the activity index Safety of
Oestrogens in Lupus Erythematosus: National
Assessment-SLEDAI [22], the damage index SLICC/ACR
Damage Index [23] and the Katz severity index [24].
Statistical analysis
We performed a descriptive analysis of the clinical, epi-
demiological, autoimmune and therapeutic characteris-
tics of all patients with SLE with or without
polyautoimmunity. Qualitative variables were expressed
as absolute numbers and percentages; quantitative vari-
ables were expressed as mean (S.D.) or median [inter-
quartile range (IQR)], as applicable.
The v2 and an ANOVA or Kruskal–Wallis test (depend-
ing on normality) were performed to compare the main
characteristics between four groups of patients: (i)
patients with SLE and no other autoimmune disease; (ii)
patients with a family history of SLE; (iii) patients with
autoimmune thyroiditis; and (iv) patients with another
SARD. Survival was analysed based on Kaplan–Meier
curves in order to compare time on antimalarial drugs in
patients with SLE with and without polyautoimmunity or
positive antibody titres. Finally, a binary logistic regres-
sion analysis was performed (dependent variable: poly-
autoimmunity) to explore variables associated with
polyautoimmunity identified in the bivariate analysis and/
or of clinical interest. Multicollinearity of independent
variables was verified using the Pearson correlation co-
efficient (r> 0.4). The analysis was performed using
Rcomander.
Results
Of the 4037 patients with SLE recruited in RELESSER-
TRANS, 3679 (91.1%) fulfilled four or more ACR criteria
for SLE. Most patients were women (90.3%) and white
(93.1%), and the median (IQR) age was 44.0 (35.0–56.0)
years.
Polyautoimmunity
A total of 502 of the 3679 (13.6%) patients with SLE had
polyautoimmunity, and 51 (1.4%) had MAS. Most
patients with polyautoimmunity were white women
(94.4%) with long-term disease. The most common clin-
ical manifestations in patients with polyautoimmunity
were arthritis, cutaneous abnormalities and RP. Most
patients (99%) had positive ANA titres, with a predomin-
ance of anti-DNA, anti-Ro and anti-RNP antibodies. As
for treatment, the vast majority had received CS and
antimalarial drugs at some time during the course of








atology/article/59/8/2043/5662444 by guest on 03 N
ovem
ber 2020
their disease. Table 1 shows a comparison of the results
for the whole SLE group (n¼ 3679) and the polyautoim-
munity and SLE paients (n¼502).
The autoimmune diseases most commonly associated
with SLE were autoimmune thyroiditis [289/3679 (7.9%)]
and other autoimmune diseases [227/3679 (6.2%)].
In the latter group, 97/3679 (2.6%) had MCTD and
130/3679 (3.5%) had RA, SSc or inflammatory myop-
athy. A total of 517/3679 (14.1%) patients had second-
ary SS and 505/3679 (13.7%) had secondary APS.
A family history of SARD was recorded in 433 patients
(11.8%) with SLE.
TABLE 1 Characteristics of whole SLE group (n¼3679) with the polyautoimmunity and SLE patients (n¼502)
Variable Whole SLE group (n 5 3679) Polyautoimmunity (n 5 502) P-value
Epidemiological characteristics
Sex (female), n (%) 3315 (90.3) 473 (94.4) 0.001
Age at SLE diagnosis (years), mean (S.D.) 34.6 (14.6) 36.7 (14.2) 0.220
Age at the time of inclusion (years), mean (S.D.) 46.2 (14.8) 48.8 (14.6) 0.189
Disease duration (months), median (IQR) 165.4 (82.0–234.0) 162.0 (83.0–243.0) 0.159
Family historya, n (%) 433 (16.0) 60 (15.7) 0.902
Clinical manifestations
SS, n (%) 517 (14.4) 127 (25.7) <0.001
APS, n (%) 505 (13.9) 74 (14.9) 0.486
Malar rash, n (%) 2004 (55.2) 253 (50.8) 0.100
Discoid lupus, n (%) 753 (21.0) 94 (19.1) 0.265
Photosensitivity, n (%) 2172 (60.8) 293 (59.7) 0.569
Ulcer, n (%) 1645 (46.1) 218 (44.4) 0.414
Arthritis, n (%) 2827 (77.9) 393 (79.4) 0.415
Jaccoud arthropathy, n (%) 363 (10.0) 90 (18.1) 0.005
Pleuritis, n (%) 826 (23.0) 105 (21.3) 0.357
Pericarditis, n (%) 579 (16.1) 86 (17.3) 0.404
Neurologicb, n (%) 331 (9.1) 45 (9.1) 0.989
Hematologicc, n (%) 2371 (66.0) 320 (64.9) 0.568
RP, n (%) 1200 (33.9) 226 (45.8) <0.001
Nephritis, n (%) 1101 (30.6) 131 (26.5) 0.035
Proteinuria, n (%) 1170 (32.2) 132 (26.6) 0.013
Interstitial lung disease, n (%) 73 (2.0) 25 (5.0) 0.010
Pulmonary hypertension, n (%) 8 (2.4) 17 (3.4) 0.157
Antibody profile
ANA, n (%) 3637 (99.1) 497 (99.0) 0.892
Anti-dsDNA antibody positivity, n (%) 2629 (73.3) 350 (71.0) 0.208
Anti-Sm antibody positivity, n (%) 737 (21.2) 110 (22.8) 0.337
Anti-RNP antibody positivity, n (%) 891 (25.2) 164 (34.1) <0.001
Anti-Ro antibody positivity, n (%) 1350 (36.0) 193 (39.9) 0.099
Anti-La antibody positivity, n (%) 690 (18.8) 104 (21.4) 0.117
LA, n (%) 638 (23.9) 70 (20.3) 0.114
aCL positivity, n (%) 759 (20.6) 96 (19.1) 0.678
Anti-beta 2 glycoprotein 1 positivity, n (%) 442 (12.0) 59 (11.8) 0.802
Severity indexes
SLICC-ACR, median (IQR) 1.1 (0.0–2.0) 1.0 (0.0–2.0) 0.108
Katz index, median (IQR) 2.5 (1.0–3.0) 2.0 (1.0–3.0) 0.915
Mortality, n (%) 211 (6.6) 43 (8.4) 0.124
Treatment
Glucocorticoids, n (%) 3112 (88.9) 439 (91.1) 0.224
MTX, n (%) 579 (16.6) 120 (24.7) <0.001
Antimalarials, n (%) 2899 (83.3) 369 (76.7) <0.001
Time on antimalarials (months), median (IQR) 123 (62.0–204.0) 113.0 (50.0–192.0)
AZA, n (%) 1143 (33.0) 173 (36.0) 0.129
CYC, n (%) 780 (22.5) 95 (19.7) 0.126
Mycophenolate, n (%) 525 (15.2) 60 (12.4) 0.075
Rituximab, n (%) 227 (6.5) 44 (9.1) 0.170
Immunoglobulin, n (%) 154 (4.5) 23 (4.8) 0.721
aFamily history: family history of systemic autoimmune rheumatic disease. bNeurologic: seizure and psychosis.
cHematologic: haemolytic anaemia, leukopoenia and thrombocytopenia. IQR: interquartile range.
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Characteristics of the subtypes of polyautoimmunity
Table 2 shows the characteristics of the various sub-
groups associated with polyautoimmunity compared
with patients with SLE who did not have polyautoim-
munity. As shown, almost all differences were concen-
trated in patients with polyautoimmunity associated with
another SARD, whereas patients with autoimmune thy-
roiditis or a family history of SARD had similar charac-
teristics to patients with SLE but not polyautoimmunity.
Female sex was generally more frequent in all polyau-
toimmunity subphenotypes, whereas age and duration
of SLE were higher in patients with polyautoimmunity
and associated SARDs. However, other epidemiological
characteristics such as race and smoking did not differ
significantly between groups. As for clinical manifesta-
tions, patients with polyautoimmunity and another SARD
less frequently had photosensitivity, malar rash, protein-
uria and kidney disease. However, Jaccoud arthropathy,
RP, interstitial lung disease, pulmonary hypertension
and secondary SS were much more common.
The abovementioned associations were observed in
patients with MAS as an extreme subphenotype of poly-
autoimmunity, although the association was stronger:
they were all women (100%), had a lower frequency of
kidney disease (16.0 vs 31.3%; P ¼ 0.024), and
had double the number of cases with secondary SS [n
(%) ¼51.0 vs 12.6; P < 0.00], RP (87.8 vs 31.9; P <
0.001), interstitial lung disease (6.0 vs 1.5; P < 0.001)
and Jaccoud arthropathy (28.0 vs 8.7; P < 0.001), with
respect to patients with SLE but no polyautoimmunity.
Polyautoimmunity was associated with anti-Ro/SSA
antibodies (P ¼ 0.012), and MAS was associated with
anti-RNP antibodies (P < 0.001). Other antibodies such
as aPL did not differ significantly between groups. As
for treatment, patients with polyautoimmunity, including
those with MAS, more commonly received MTX (P <
0.001), AZA (P ¼ 0.019) and rituximab (P ¼ 0.043).
However, they took antimalarial agents less frequently
(P < 0.001) or for less time [median (IQR): 56.6 (31.2–
179.3) vs 185.9 (27.5–294.0) months; P < 0.001] (Fig. 1).
Similarly, less exposure to antimalarial drugs was asso-
ciated with a greater frequency of positive anti-Ro and
anti-La titres [median (IQR): 157.0 (101.2–212.7) vs 240.0
(187.3–292.6) months; P ¼ 0.003].
Multivariate analysis
The results of the multivariate analysis in Table 3 show
that polyautoimmunity was associated with female sex,
Jaccoud arthropathy, RP, interstitial lung disease,
and positive titres for anti-Ro/SSA, anti-La/SSB and
anti-RNP antibodies. Similarly, patients with polyau-
toimmunity were 67% more likely to be treated
with MTX and 50% less likely to receive antimalarial
drugs. However, variables of severity such as
mortality or damage were not associated with
polyautoimmunity.
Discussion
Classic systemic autoimmune diseases are character-
ized by very heterogeneous clinical phenotypes and by
the fact that they share clinical manifestations and
pathogenic mechanisms. This clinical and aetiological–
pathogenic overlap has been referred to by some
authors as ‘autoimmune tautology’ [25]. The best clinical
evidence of this tautology arises from the co-occurrence
of several autoimmune diseases in the same patient (i.e.
polyautoimmunity), the progression from one phenotype
to another during the clinical course (e.g. progression
from MCTD to lupus) or the presence of overlap syn-
dromes (e.g. antisynthetase syndrome) [26, 27]. In ac-
cordance with this perspective, we found the prevalence
of polyautoimmunity to be 14% in patients with SLE and
<2% in MAS. These percentages are lower than those
reported by Rojas-Villarraga et al. [25, 28], who found a
greater prevalence of polyautoimmunity in patients with
SLE (around 40%) and of MAS (5.1%). The difference
arises from the fact that the authors considered SS and
APS to be independent entities and not secondary dis-
orders. While this approach has recently been sup-
ported by other authors [29, 30], in the present study we
adopted a traditional approach and treated them as
being secondary to SLE. However, aside from this con-
sideration, the percentages reported by these authors
for SS and APSndrome were similar to ours. In addition,
the results of our multivariate model remained un-
changed irrespective of which approach was used.
As for diseases associated with SLE, autoimmune thy-
roiditis was as frequent in the present study as the other
SARDs together, although its importance in the clinical
and epidemiological characteristics of the patients was
negligible. Autoimmune thyroiditis is the most prevalent
autoimmune disease in the general population [25, 31].
Although their aetiology is still poorly understood, genet-
ic, immunological, hormonal and environmental factors
are major predisposing and triggering factors [32].
The finding that polyautoimmunity has higher female
representation than SLE is probably driven by the high
prevalence of thyroid autoimmunity, which has a much
higher female predominance than lupus, on the order of
30–40:1 vs 9:1 [33]. Female sex is also associated with
a greater frequency of MAS, which was recorded in
100% of cases in the present study. While this finding
could be biased owing to the composition of the
RELESSER Registry itself (90% are women), it has been
reported in other studies and attributed to hormones,
genetics [34] and gender-related lifestyle [35].
Rojas-Villarraga et al. [28] also highlighted that a fam-
ily history of autoimmune disease was a key risk factor
for polyautoimmunity. While this observation has been
reported in other autoimmune diseases [36–39], we
were unable to confirm it in our study, not even when
SS and APS were considered as not being secondary to
SLE.
Anti-Ro/SSA and anti-La/SSB antibodies are associ-
ated with SS, SLE and neonatal lupus. In the present
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Sex (female), n (%) 2842 (89.6) 402 (92.8) 275 (95.5) 212 (94.0) 0.006
Age at SLE diagnosis (years),
mean (S.D.)
34.6 (14.6) 31.3 (13.5) 36.1 (13.8) 37.7 (14.6) 0.051
Age at the time of inclusion (years),
mean (S.D.)
42.2 (13.8) 47.0 (14.1) 51.3 (14.8) 46.2 (14.8) 0.010
Disease duration (months),
median (IQR)
148.0 (82.0–234.0) 144.0 (81.0–231.0) 143.0 (69.0–233.0) 180.5 (106.5–259.2) 0.001
Clinical manifestations
Malar rash, n (%) 1751 (55.9) 254(59.1) 156 (54.5) 102 (44.9) 0.013
Discoid lupus, n (%) 659 (21.3) 94 (22.1) 61 (21.6) 35 (15.6) 0.161
Photosensitivity, n (%) 1879 (61.0) 264 (62.9) 181 (64.9) 121 (53.3) 0.023
Oral ulcers, n (%) 1427 (46.4) 224 (52.8) 123 (43.5) 101 (45.5) 0.348
Arthritis, n (%) 2434 (77.7) 338 (79.5) 218 (77.0) 187 (82.7) 0.179
Jaccoud arthropathy, n (%) 315 (9.9) 46 (10.7) 22 (7.7) 72 (31.9) <0.001
Pleuritis, n (%) 721 (23.2) 88 (20.9) 57 (20.2) 49 (21.7) 0.532
Pericarditis, n (%) 493 (15.9) 70 (16.6) 47 (16.5) 40 (17.7) 0.476
Proteinuria, n (%) 1001 (32.2) 126 (29.6) 87 (30.4) 45 (20.1) 0.011
Neurologicb, n (%) 286 (9.1) 44 (10.3) 20 (7.5) 26 (11.0) 0.500
Hematologicc, n (%) 2031 (65.5) 277 (64.9) 182 (64.3) 134 (60.3) 0.985
SS, n (%) 390 (12.6) 54 (12.7) 62 (21.9) 72 (31.9) <0.001
APS, n (%) 431 (13.7) 65 (15.2) 43 (15.0) 34 (15.2) 0.843
RP, n (%) 974 (31.9) 159 (37.0) 88 (31.1) 148 (66.4) <0.001
Nephritis, n (%) 970 (31.3) 124 (28.9) 79 (27.7) 51 (23.0) 0.133
Interstitial lung disease, n (%) 48 (1.5) 10 (2.3) 2 (0.7) 23 (10.2) <0.001
Pulmonary hypertension, n (%) 71 (2.3) 13 (3.1) 5 (1.7) 11 (4.9) <0.001
Antibody profile
ANA, n (%) 3140 (99.1) 428 (99.1) 288 (99.7) 223 (98.2) 0.356
Anti-dsDNA antibody
positivity, n (%)
2279 (73.7) 320 (76.4) 206 (73.0) 154 (68.4) 0.050
Anti-Sm antibody positivity, n (%) 627 (21.0) 108 (26.4) 58 (21.2) 56 (25.6) 0.435
Anti-RNP antibody positivity, n (%) 727 (23.8) 114 (27.3) 55 (20.2) 117 (52.5) <0.001
Anti-Ro antibody positivity, n (%) 1210 (38.1) 185 (44.7) 111 (40.4) 90 (41.5) 0.179
Anti-La antibody positivity, n (%) 586 (18.4) 96 (23.1) 63 (22.9) 43 (19.3) 0.057
aCL positivity, n (%) 728 (25.1) 117 (26.3) 70 (24.6) 48 (22.0) 0.518
Anti-beta 2 glycoprotein 1
positivity, n (%)
270 (14.2) 56 (12.5) 30 (15.0) 13 (11.0) 0.166
LA, n (%) 568 (24.4) 94 (27.4) 42 (20.1) 27 (22.5) 0.255
Treatment
Antimalarials, n (%) 2530 (84.3) 356 (86.0) 231 (83.4) 151 (69.0) <0.001
Time on antimalarials (months),
median (IQR)
60.0 (25.0–120.0) 58.0 (27.5–109.5) 48.0 (22.5–79.5) 36.0 (13.2–108.0) 0.008
MTX, n (%) 459 (15.3) 81 (19.8) 48 (17.1) 76 (34.9) <0.001
AZA, n (%) 970 (32.5) 135 (32.8) 82 (29.7) 95 (44.0) 0.001
CYC, n (%) 685 (22.9) 85 (20.9) 52 (18.7) 44 (20.2) 0.339
Mycophenolate, n (%) 465 (15.7) 80 (19.7) 40 (14.3) 20 (9.2) 0.145
Rituximab, n (%) 183 (6.1) 31 (7.6) 22 (7.9) 23 (10.6) 0.038
Immunoglobulins, n (%) 131 (4.4) 22 (5.4) 18 (6.5) 5 (2.3) 0.210
The P-value is generated based on the v2 test, ANOVA or Kruskal–Wallis test (depending on normality). aSLE 4 criteria
without polyautoimmunity. bNeurologic: seizure and psychosis. cHematologic: haemolytic anaemia, leukopoenia and
thrombocytopenia. SARD: systemic autoimmune rheumatic disease; IQR: interquartile range.
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study, these autoantibodies were also independently
associated with polyautoimmunity. Despite the fact that
this finding has been reported in studies that consider
SS to be a separate entity [28, 29], we found that the
association persisted even with autoimmune diseases
other than this syndrome, such as autoimmune thyroidi-
tis, RA, scleroderma, MCTD and inflammatory myositis.
Other authors found that polyautoimmunity was more
frequent in patients with SSc and positive anti-Ro titres
[40]. The association between these antibodies and pol-
yautoimmunity could be explained by the process
known as ‘epitope spreading’, in which an immune
response is modified over time and the changes are
associated with changes in the clinical picture [41, 42].
Another interesting aspect of the determinants of
poly-autoimmunity is their influence on prognosis. While
patients with polyautoimmunity in the present study less
frequently had nephritis, our multivariate analysis
showed that they were three times more likely to have
interstitial lung disease and twice as likely to have
Jaccoud arthropathy and RP. Interstitial lung disease
and RP have been reported to be more frequent in
patients with SLE and overlapping SS, SSc and MCTD
[43, 44]. Our data confirm this observation. Jaccoud
arthropathy is sometimes observed in patients with
long-term SLE and is associated with disability. SLE has
previously been reported to overlap with antisynthetase
syndrome, RP and scleroderma [45], in addiction to
MCTD [46]. In all cases, as in our study, this clinical
problem was associated with long-term disease and in-
flammation of the joints and tendons, which was some-
times subclinical [47]. Rojas-Villarraga et al. [28] found
that joint involvement was a risk factor associated with
polyautoimmunity and reported that patients with SLE
and joint involvement were twice as likely to develop
polyautoimmunity as patients with SLE without arthritis.
Lastly, a key aspect of systemic autoimmune diseases
as a specific group is that they share similar therapies.
Therefore, a detailed knowledge of the aetiology and
pathogenesis of polyautoimmunity could enable the de-
velopment of new therapeutic targets in these diseases.
In this sense, we found that patients with polyautoim-
munity were almost 50% less likely to receive antimalar-
ial drugs and that patients who took these drugs did so
for shorter periods. While the design of our study does
not allow us to establish causality, this finding leads us
to take two aspects into consideration. First, antimalarial
drugs have a wide range of beneficial effects in patients
with SLE and other autoimmune diseases (e.g. SS, DM).
A particularly interesting effect for us is that patients
with incomplete lupus (i.e. fewer than four criteria)
treated with HCQ take longer to develop SLE than those
who do not receive the drug [48]. Second, antimalarial
agents are less frequently indicated in patients with pol-
yautoimmunity, owing to the poorer response or the
presence of manifestations such as Jaccoud arthropathy
that lead physicians to prefer other drugs, such as MTX.
Nevertheless, MTX seems less likely, because antimalar-
ial drugs are the agents of choice for treatment of joint
manifestations and because they tend to be used in
combination with other drugs, even in severe complica-
tions [49]. Unfortunately, the relationship between poly-
autoimmunity and treatments received in SLE, as well
as in other systemic autoimmune diseases, has not
been as well studied as other aetiological, epidemio-
logical and clinical-analytical factors.
Although polyautoimmunity has been addressed from
various angles by a small number of authors, our study
analyses a large number of patients, serves to validate
current knowledge and provides data on a predominant-
ly white Spanish population. However, our study is
FIG. 1 Kaplan–Meier survival estimates
TABLE 3 Binary logistic regression analysis of the charac-
teristics associated with polyautoimmunity in patients
with SLE
Predictor OR (95% CI) P-value
Female sex 1.721 (1.074, 2.729) 0.024
RP 1.630 (1.292, 2.056) <0.001
Interstitial lung disease 3.350 (1.840, 6.009) <0.001
Anti-RNP positivity 1.486 (1.163, 1.900) 0.002
Anti-Ro and/or anti-La
antibody positivity
2.039 (1.555, 2.673) <0.001
Jaccoud arthropathy 1.921 (1.402, 2.634) <0.001
Antimalarials 0.509 (0.384, 0.675) <0.001
MTX 1.666 (1.268, 2.189) <0.001
Nagelkerke R2 ¼0.122. Variables included: sex, age at the
time of RELESSER-TRANS inclusion, duration of disease,
proteinuria, anti-Ro and anti-La antibodies, RP, interstitial
lung disease, anti-RNP, use of MTX, use of antimalarial
treatment, Jaccoud arthropathy, mortality, SLICC-ACR.
Dependent variable: polyautoimmunity. OR: odds ratio;
RELESSER-TRANS: Spanish Society of Rheumatology
Lupus Registry, cross-sectional phase.
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subject to the methodological limitations that are inher-
ent to all cross-sectional analyses of national registries.
Over 40 centres throughout Spain participated in the
registry. Since there was no centralized laboratory, the
accuracy of the serological data may have been
affected. It is also limited by the fact that most of the
comorbid autoimmune diseases were not collected ex-
haustively or independently. Nevertheless, the diseases
we did record account for 90% of those diseases that
are commonly associated with patients who have SLE.
In conclusion, polyautoimmunity in the present cohort
of patients with SLE was not uncommon and was asso-
ciated with female sex, manifestations of poor prognosis
(interstitial lung disease, Jaccoud arthropathy and RP),
and specific antibody profiles (anti-Ro/SSA, anti-La/SSB
and anti-RNP). Patients received more immunosuppres-
sants and fewer antimalarial drugs. While this finding
has to be confirmed, the lower frequency of antimalarial
drugs in patients with polyautoimmunity suggests that
these agents could have a protective effect against
polyautoimmunity.
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